Related Experiment Video
Updated: Apr 28, 2026

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
Published on: July 28, 2022
Looking for new treatments of Infantile Colic
Francesco Savino1, Simone Ceratto, Angela De Marco
1Dipartimento di Scienze della Sanità Pubblica e Pediatriche, Università di Torino, Ospedale Infantile Regina Margherita - Città della Salute e della Scienza di Torino, Turin, Italy. francesco.savino@unito.it.
Insights
Infantile colic, a common infant issue, lacks clear treatment guidelines. Emerging evidence suggests dietary changes, probiotics, and certain medications may help, but more research is needed for effective management.
Area of Science:
- Pediatrics
- Gastroenterology
- Microbiome Research
Background:
- Infantile colic is a frequent, benign condition impacting families and pediatric consultations.
- Lack of evidence-based guidelines leads to underestimation and inconsistent management by healthcare professionals.
- Current understanding highlights the need for consensus on effective treatment strategies.
Purpose of the Study:
- To review current evidence on various management and treatment options for infantile colic.
- To explore the role of diet, pharmacology, complementary therapies, and behavioral interventions.
- To highlight the emerging role of microbiota and probiotics in infantile colic.
Main Methods:
- Literature review of dietary, pharmacological, complementary, and behavioral therapies.
- Analysis of studies investigating specific agents like Simethicone and Cimetropium Bromide.
- Examination of research on the role of gut microbiota and probiotic interventions.
Main Results:
- Dietary approaches, including special formulas with prebiotics/probiotics, show promise but require further validation.
- Simethicone may reduce bloating; Cimetropium Bromide shows potential for severe colic but needs more study.
- Limited evidence supports complementary/behavioral therapies; probiotics are a focus, but strain-specific efficacy is unclear.
Conclusions:
- There is no current consensus on infantile colic management, necessitating further evidence-based research.
- Dietary modifications and novel pharmacological agents warrant continued investigation.
- Understanding the role of microbiota is crucial for developing targeted, effective probiotic therapies for infantile colic.
Abstract:
Infantile colic is a common disturbance occurring in the first three months of life. It is a benign condition and one of the main causes of pediatric consultation in the early part of life because of its great impact on family life. Some pediatricians are prone to undervalue this issue mainly because of the lack of evidence based medicine guidelines. Up to now, there is no consensus concerning management and treatment. Literature reports growing evidence about the effectiveness of dietary, pharmacological, complementary and behavioral therapies as options for the management of infantile colic. Dietary approach, usually based on the avoidance of cow's milk proteins in breast-feeding mothers and bottle-fed infants, more recently has seen the rise of new special formulas, such as partially hydrolyzed proteins and low lactose added with prebiotics or probiotics: their efficacy needs to be further documented. Investigated pharmacological agents are Simethicone and Cimetropium Bromide: the first is able to reduce bloating while the second could reduce fussing crying, but it has been tested only for severe infantile colic. No other pain relieving agents have been proposed until now, but some clinical trials are ongoing for new drugs.There is limited evidence supporting the use of complementary and alternative treatments (herbal supplements, manipulative approach and acupuncture) or behavioral interventions.Recent studies have focused the role of microbiota in the pathogenesis of this disturb and so new treatments, such as probiotics, have been proposed, but only few strains have been tested.Further investigations are needed in order to provide evidence-based guidelines.
Related Concept Videos
Drugs for Treatment of Constipation-Predominant IBS
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
Adsorbents...
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...

